Clinical trialNCT00509301CompletedPhase 1Interventional

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

SponsorPeregrine PharmaceuticalsEnrollment12Recurrent Glioblastoma Multiforme

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out." This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer. PURPOSE: This trial is studying the safety and radiation distribution of Cotara® in patients with recurrent glioblastoma multiforme.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew E Sloan, MD, FACS
University Hospitals Cleveland Medical Center
Principal Investigator
clinicaltrials.gov ↗
Kenneth M Spicer, MD PhD
Medical University of South Carolina
Principal Investigator
clinicaltrials.gov ↗
Kevin D Judy, MD
University of Pennsylvania
Principal Investigator
clinicaltrials.gov ↗
Sunil J Patel, MD
Medical University of South Carolina
Principal Investigator
clinicaltrials.gov ↗
William R Shapiro, MD
Barrow Neurological Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Barrow Neurological Institute
Phoenix, Arizona, United States
University Hospitals Case Medical Center
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

131-I-chTNT-1/B MAB

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2006
Primary completion: 31 Mar 2010
Completion: 31 Mar 2010
Last update posted: 5 Aug 2011
Registered enrollment: 12
Registry id: NCT00509301

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.